Download PDF
Digestive Disease Interventions 2020; 04(01): 019-030
DOI: 10.1055/s-0040-1705103
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Multidisciplinary Approach for Liver Transplantation in Patients with Nonalcoholic Steatohepatitis: It Takes a Village

Eugenia Tsai   *
1   Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas
2   Liver Transplantation Center, University of Texas Health San Antonio, San Antonio, Texas
,
Ronit Patnaik   *
2   Liver Transplantation Center, University of Texas Health San Antonio, San Antonio, Texas
,
Naim Alkhouri
1   Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas
2   Liver Transplantation Center, University of Texas Health San Antonio, San Antonio, Texas
› Author Affiliations
Further Information

Publication History

11 October 2019

05 January 2020

Publication Date:
02 March 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in Western countries, and its aggressive form, nonalcoholic steatohepatitis (NASH), is a leading cause of cirrhosis and end-stage liver disease. The total number of new liver transplantation waitlist registrants with NASH continues to increase rapidly, making NASH the second most common indication for liver transplantation. Compared with recipients for other etiologies, patients with NASH often have higher rates of obesity, diabetes, dyslipidemia, hypertension, kidney disease, and cardiac disease. Many of these medical comorbidities are independently associated with increased preoperative risk and both short- and long-term complications. The presence of these particular risk factors necessitates the need for early detection, medical optimization, and careful preoperative care. Bariatric surgery is an effective strategy for weight loss and ultimately reducing obesity-related medical complications. In select patients, bariatric surgery—before, during, or after liver transplantation—may be useful to help improve posttransplant outcomes. NAFLD/NASH can present after liver transplantation and occurs as either recurrent or de novo disease. Posttransplant NAFLD occurs in the setting of metabolic syndrome, immunosuppression use, and genetic determinants. Future studies and efforts should focus on optimizing medical management strategies to further improve transplant outcomes in patients with NAFLD.

Keywords

nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - metabolic syndrome - liver transplant - recurrent NAFLD - de novo NAFLD

Disclosure

Naim Alkhouri is on the speaker bureau for Intercept and he served as a consultant for Intercept, Allergan, and Zydus.


* First co-authors.


 

  • References

  • 1 European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64 (06) 1388-1402
    CrossrefPubMedGoogle Scholar
  • 2 Singal AK, Hasanin M, Kaif M, Wiesner R, Kuo YF. Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States. Transplantation 2016; 100 (03) 607-612
    CrossrefPubMedGoogle Scholar
  • 3 Banini B, Mota M, Bhnke M. , et al. NASH surpasses HCV as top etiology for adults listed for liver transplant. Presented at the American College of Gastroenterology Annual Scientific Meeting; October 14, 2016 ; Las Vegas, NV
    PubMed
  • 4 Cholankeril G, Wong RJ, Hu M. , et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci 2017; 62 (10) 2915-2922
    CrossrefPubMedGoogle Scholar
  • 5 Jayakumar S. Liver transplantation for non-alcoholic fatty liver disease—a review. http://amj.amegroups.com/article/view/4320 . Accessed January 1, 2018
    PubMedGoogle Scholar
  • 6 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23 (47) 8263-8276
    CrossrefPubMedGoogle Scholar
  • 7 Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013; 13: 40
    CrossrefPubMedGoogle Scholar
  • 8 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: an updated narrative review. World J Hepatol 2015; 7 (03) 575-582
    CrossrefPubMedGoogle Scholar
  • 9 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52 (05) 1836-1846
    CrossrefPubMedGoogle Scholar
  • 10 Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways. Curr Hepatol Rep 2018; 17 (04) 350-360
    CrossrefPubMedGoogle Scholar
  • 11 Kim WR, Lake JR, Smith JM. , et al. OPTN/SRTR 2016 Annual Data Report: liver. Am J Transplant 2018; 18 (Suppl. 01) 172-253
    CrossrefPubMedGoogle Scholar
  • 12 Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95 (05) 755-760
    CrossrefPubMedGoogle Scholar
  • 13 Grundy SM, Cleeman JI, Daniels SR. , et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17) 2735-2752
    CrossrefPubMedGoogle Scholar
  • 14 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34 (03) 274-285
    CrossrefPubMedGoogle Scholar
  • 15 Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016; 17 (05) 774
    CrossrefPubMedGoogle Scholar
  • 16 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
    CrossrefPubMedGoogle Scholar
  • 17 Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313 (22) 2263-2273
    CrossrefPubMedGoogle Scholar
  • 18 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67 (01) 123-133
    CrossrefPubMedGoogle Scholar
  • 19 Mccullough A. The epidemiology and risk factors of NASH. In: Farrell GC, George J, de la M. Hall P, McCullough AJ. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell; 2007. :23–37
  • 20 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56 (06) 1384-1391
    CrossrefPubMedGoogle Scholar
  • 21 Younossi ZM, Otgonsuren M, Henry L. , et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015; 62 (06) 1723-1730
    CrossrefPubMedGoogle Scholar
  • 22 Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin 2019; 1 (October): 1-9
    PubMedGoogle Scholar
  • 23 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8 (06) 429-436
    CrossrefPubMedGoogle Scholar
  • 24 Wong RJ, Aguilar M, Cheung R. , et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148 (03) 547-555
    CrossrefPubMedGoogle Scholar
  • 25 Noureddin M, Vipani A, Bresee C. , et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018; 113 (11) 1649-1659
    CrossrefPubMedGoogle Scholar
  • 26 Siddique O, Joseph-Talreja M, Yoo ER. , et al. Rising rate of liver transplantation in the baby boomer generation with non-alcoholic steatohepatitis in the United States. J Clin Transl Hepatol 2017; 5 (03) 193-196
    PubMedGoogle Scholar
  • 27 Cholankeril G, Yoo ER, Perumpail RB. , et al. Rising rates of hepatocellular carcinoma leading to liver transplantation in baby boomer generation with chronic hepatitis C, alcohol liver disease, and nonalcoholic steatohepatitis-related liver disease. Diseases 2017; 5 (04) 20
    CrossrefPubMedGoogle Scholar
  • 28 O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011; 9 (08) 700-704 .e1
    CrossrefPubMedGoogle Scholar
  • 29 Thuluvath PJ, Hanish S, Savva Y. Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic, or AIH cirrhosis. Transplantation 2019; 103 (01) 113-121
    CrossrefPubMedGoogle Scholar
  • 30 Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307 (05) 491-497
    CrossrefPubMedGoogle Scholar
  • 31 Marchesini G, Brizi M, Morselli-Labate AM. , et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (05) 450-455
    CrossrefPubMedGoogle Scholar
  • 32 Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141 (04) 1249-1253
    CrossrefPubMedGoogle Scholar
  • 33 LaMattina JC, Foley DP, Fernandez LA. , et al. Complications associated with liver transplantation in the obese recipient. Clin Transplant 2012; 26 (06) 910-918
    CrossrefPubMedGoogle Scholar
  • 34 Nair S, Vanatta JM, Arteh J, Eason JD. Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study. Liver Transpl 2009; 15 (11) 1519-1524
    CrossrefPubMedGoogle Scholar
  • 35 Conzen KD, Vachharajani N, Collins KM. , et al. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. HPB (Oxford) 2015; 17 (03) 251-257
    CrossrefPubMedGoogle Scholar
  • 36 Dureja P, Mellinger J, Agni R. , et al. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91 (06) 684-689
    CrossrefPubMedGoogle Scholar
  • 37 Tai C-M, Huang C-K, Hwang J-C. , et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 2012; 22 (07) 1016-1021
    CrossrefPubMedGoogle Scholar
  • 38 Lassailly G, Caiazzo R, Buob D. , et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149 (02) 379-388 , quiz e15–e16
    CrossrefPubMedGoogle Scholar
  • 39 Praveen Raj P, Gomes RM, Kumar S. , et al. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis 2015; 11 (06) 1315-1322
    CrossrefPubMedGoogle Scholar
  • 40 Kwak M, Mehaffey JH, Hawkins RB, Hsu A, Schirmer B, Hallowell PT. Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: a propensity matched analysis. Am J Surg 2019; S0002-9610(19)30853-0
    PubMedGoogle Scholar
  • 41 Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis 2016; 12 (01) 127-131
    CrossrefPubMedGoogle Scholar
  • 42 von Schönfels W, Beckmann JH, Ahrens M. , et al. Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surg Obes Relat Dis 2018; 14 (10) 1607-1616
    CrossrefPubMedGoogle Scholar
  • 43 Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9 (10) 897-901
    CrossrefPubMedGoogle Scholar
  • 44 Tichansky DS, Madan AK. Laparoscopic Roux-en-Y gastric bypass is safe and feasible after orthotopic liver transplantation. Obes Surg 2005; 15 (10) 1481-1486
    CrossrefPubMedGoogle Scholar
  • 45 Nickel F, Tapking C, Benner L. , et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up: BariScan study. Obes Surg 2018; 28 (05) 1342-1350
    CrossrefPubMedGoogle Scholar
  • 46 Luger M, Kruschitz R, Kienbacher C. , et al. Prevalence of liver fibrosis and its association with non-invasive fibrosis and metabolic markers in morbidly obese patients with vitamin D deficiency. Obes Surg 2016; 26 (10) 2425-2432
    CrossrefPubMedGoogle Scholar
  • 47 Lager CJ, Esfandiari NH, Subauste AR. , et al. Roux-En-Y gastric bypass vs. sleeve gastrectomy: balancing the risks of surgery with the benefits of weight loss. Obes Surg 2017; 27 (01) 154-161
    CrossrefPubMedGoogle Scholar
  • 48 Diwan TS, Lichvar AB, Leino AD. , et al. Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. Clin Transplant 2017 31. (06)
    PubMedGoogle Scholar
  • 49 Heimbach JK, Watt KDS, Poterucha JJ. , et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013; 13 (02) 363-368
    CrossrefPubMedGoogle Scholar
  • 50 Zamora-Valdes D, Watt KD, Kellogg TA. , et al. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology 2018; 68 (02) 485-495
    CrossrefPubMedGoogle Scholar
  • 51 Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J Intern Med 2015; 277 (05) 573-584
    CrossrefPubMedGoogle Scholar
  • 52 Pareja E, Cortes M, Navarro R, Sanjuan F, López R, Mir J. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc 2010; 42 (08) 2970-2972
    CrossrefPubMedGoogle Scholar
  • 53 Duffy JP, Hong JC, Farmer DG. , et al. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg 2009; 208 (05) 896-903 , discussion 903–905
    CrossrefPubMedGoogle Scholar
  • 54 Tsamalaidze L, Stauffer JA, Arasi LC. , et al. Laparoscopic sleeve gastrectomy for morbid obesity in patients after orthotopic liver transplant: a matched case-control study. Obes Surg 2018; 28 (02) 444-450
    CrossrefPubMedGoogle Scholar
  • 55 Morris MC, Jung AD, Kim Y. , et al. Delayed sleeve gastrectomy following liver transplantation: a 5-year experience. Liver Transpl 2019; 25 (11) 1673-1681
    CrossrefPubMedGoogle Scholar
  • 56 Kasturiratne A, Weerasinghe S, Dassanayake AS. , et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013; 28 (01) 142-147
    PubMedGoogle Scholar
  • 57 Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29 (01) 113-119
    CrossrefPubMedGoogle Scholar
  • 58 Brunt EM, Wong VW-S, Nobili V. , et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 1: 15080
    CrossrefPubMedGoogle Scholar
  • 59 Cui J, Chen C-H, Lo M-T. , et al; For The Genetics Of Nafld In Twins Consortium. Shared genetic effects between hepatic steatosis and fibrosis: a prospective twin study. Hepatology 2016; 64 (05) 1547-1558
    CrossrefPubMedGoogle Scholar
  • 60 Loomba R, Abraham M, Unalp A. , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56 (03) 943-951
    CrossrefPubMedGoogle Scholar
  • 61 Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 2014; 109 (07) 1020-1025
    CrossrefPubMedGoogle Scholar
  • 62 Park CW, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 2011; 25 (06) E606-E611
    CrossrefPubMedGoogle Scholar
  • 63 Carter D, Dieterich DT, Chang C. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in liver transplantation. Clin Liver Dis 2018; 22 (01) 213-227
    CrossrefPubMedGoogle Scholar
  • 64 Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002; 74 (07) 1007-1012
    CrossrefPubMedGoogle Scholar
  • 65 Younossi ZM, Stepanova M, Saab S. , et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther 2014; 40 (06) 686-694
    CrossrefPubMedGoogle Scholar
  • 66 Hoehn RS, Singhal A, Wima K. , et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. Liver Int 2015; 35 (07) 1902-1909
    CrossrefPubMedGoogle Scholar
  • 67 Gray M, Singh S, Zucker SD. Influence of type 2 diabetes mellitus and preoperative hemoglobin A1c levels on outcomes of liver transplantation. Hepatol Commun 2019; 3 (04) 574-586
    CrossrefPubMedGoogle Scholar
  • 68 McCullough K, Sharma P, Ali T. , et al. Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 2012; 27 (05) 1812-1821
    CrossrefPubMedGoogle Scholar
  • 69 Stevens PE, Levin A. ; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158 (11) 825-830
    CrossrefPubMedGoogle Scholar
  • 70 Singal AK, Ong S, Satapathy SK, Kamath PS, Wiesner RH. Simultaneous liver kidney transplantation. Transpl Int 2019; 32 (04) 343-352
    CrossrefPubMedGoogle Scholar
  • 71 Stefan N, Hennige AM, Staiger H. , et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006; 29 (04) 853-857
    CrossrefPubMedGoogle Scholar
  • 72 Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010; 21 (03) 406-412
    CrossrefPubMedGoogle Scholar
  • 73 Targher G, Chonchol M, Bertolini L. , et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19 (08) 1564-1570
    CrossrefPubMedGoogle Scholar
  • 74 Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5 (12) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 75 Yasui K, Sumida Y, Mori Y. , et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011; 60 (05) 735-739
    CrossrefPubMedGoogle Scholar
  • 76 Musso G, Gambino R, Tabibian JH. , et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11 (07) e1001680
    CrossrefPubMedGoogle Scholar
  • 77 Mantovani A, Zaza G, Byrne CD. , et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism 2018; 79: 64-76
    CrossrefPubMedGoogle Scholar
  • 78 Wong F, Reddy KR, O'Leary JG. , et al. Impact of chronic kidney disease on outcomes in cirrhosis. Liver Transpl 2019; 25 (06) 870-880
    CrossrefPubMedGoogle Scholar
  • 79 Agopian VG, Kaldas FM, Hong JC. , et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012; 256 (04) 624-633
    CrossrefPubMedGoogle Scholar
  • 80 Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004; 10 (12) 1441-1453
    CrossrefPubMedGoogle Scholar
  • 81 Ekstedt M, Franzén LE, Mathiesen UL. , et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 (04) 865-873
    CrossrefPubMedGoogle Scholar
  • 82 Pruthi J, Medkiff KA, Esrason KT. , et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7 (09) 811-815
    CrossrefPubMedGoogle Scholar
  • 83 Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002; 132 (04) 775-780 , discussion 780
    CrossrefPubMedGoogle Scholar
  • 84 Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6 (04) (Suppl. 01) S44-S52
    CrossrefPubMedGoogle Scholar
  • 85 Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112 (20) 3066-3072
    CrossrefPubMedGoogle Scholar
  • 86 Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14 (11) 1648-1654
    CrossrefPubMedGoogle Scholar
  • 87 Hanouneh IA, Feldstein AE, McCullough AJ. , et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14 (09) 1287-1293
    CrossrefPubMedGoogle Scholar
  • 88 Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56 (05) 1741-1750
    CrossrefPubMedGoogle Scholar
  • 89 Albeldawi M, Aggarwal A, Madhwal S. , et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl 2012; 18 (03) 370-375
    CrossrefPubMedGoogle Scholar
  • 90 Patel SS, Lin FP, Rodriguez VA. , et al. The relationship between coronary artery disease and cardiovascular events early after liver transplantation. Liver Int 2019; 39 (07) 1363-1371
    CrossrefPubMedGoogle Scholar
  • 91 Patel SS, Rodriguez VA, Siddiqui MB. , et al. The impact of coronary artery disease and statins on survival after liver transplantation. Liver Transpl 2019; 25 (10) 1514-1523
    CrossrefPubMedGoogle Scholar
  • 92 Ehtisham J, Altieri M, Salamé E, Saloux E, Ollivier I, Hamon M. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 16 (05) 550-557
    CrossrefPubMedGoogle Scholar
  • 93 D'Agostino Sr RBS, Vasan RS, Pencina MJ. , et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117 (06) 743-753
    CrossrefPubMedGoogle Scholar
  • 94 Sarnak MJ, Levey AS, Schoolwerth AC. , et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108 (17) 2154-2169
    CrossrefPubMedGoogle Scholar
  • 95 Maor-Kendler Y, Batts KP, Burgart LJ. , et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000; 70 (02) 292-297
    CrossrefPubMedGoogle Scholar
  • 96 Pais R, Barritt IV AS, Calmus Y. , et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol 2016; 65 (06) 1245-1257
    CrossrefPubMedGoogle Scholar
  • 97 Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012; 18 (01) 29-37
    CrossrefPubMedGoogle Scholar
  • 98 Vallin M, Guillaud O, Boillot O, Hervieu V, Scoazec JY, Dumortier J. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. Liver Transpl 2014; 20 (09) 1064-1071
    CrossrefPubMedGoogle Scholar
  • 99 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16 (04) 431-439
    CrossrefPubMedGoogle Scholar
  • 100 Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997; 3 (02) 177-178
    CrossrefPubMedGoogle Scholar
  • 101 Narayanan P, Mara K, Izzy M. , et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. Transplantation 2019; 103 (01) e14-e21
    CrossrefPubMedGoogle Scholar
  • 102 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30 (06) 1356-1362
    CrossrefPubMedGoogle Scholar
  • 103 Germani G, Laryea M, Rubbia-Brandt L. , et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation. Transplantation 2019; 103 (01) 57-67
    CrossrefPubMedGoogle Scholar
  • 104 Watt KD, Dierkhising R, Fan C. , et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant 2013; 13 (09) 2450-2457
    CrossrefPubMedGoogle Scholar
  • 105 Petta S, Grimaudo S, Cammà C. , et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 56 (06) 1356-1362
    CrossrefPubMedGoogle Scholar
  • 106 Finkenstedt A, Auer C, Glodny B. , et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013; 11 (12) 1667-1672
    CrossrefPubMedGoogle Scholar
  • 107 Hejlova I, Honsova E, Sticova E. , et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl 2016; 22 (05) 644-655
    CrossrefPubMedGoogle Scholar
  • 108 Seo S, Maganti K, Khehra M. , et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007; 13 (06) 844-847
    CrossrefPubMedGoogle Scholar
  • 109 Dumortier J, Giostra E, Belbouab S. , et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 2010; 105 (03) 613-620
    CrossrefPubMedGoogle Scholar
  • 110 Galvin Z, Rajakumar R, Chen E. , et al. Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis. Liver Transpl 2019; 25 (01) 56-67
    CrossrefPubMedGoogle Scholar
  • 111 Marsman WA, Wiesner RH, Rodriguez L. , et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62 (09) 1246-1251
    CrossrefPubMedGoogle Scholar
  • 112 Orman ES, Barritt IV AS, Wheeler SB, Hayashi PH. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl 2013; 19 (01) 59-68
    CrossrefPubMedGoogle Scholar
  • 113 Barnard A, Konyn P, Saab S. Medical management of metabolic complications of liver transplant recipients. Gastroenterol Hepatol (N Y) 2016; 12 (10) 601-608
    PubMedGoogle Scholar
  • 114 Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9 (11) S44-S47
    CrossrefPubMedGoogle Scholar
  • 115 Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57 (10) 1441-1447
    CrossrefPubMedGoogle Scholar
  • 116 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (09) 1265-1269
    CrossrefPubMedGoogle Scholar
  • 117 Hashemi S-A, Alavian S-M, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Caspian J Intern Med 2016; 7 (04) 242-252
    PubMedGoogle Scholar
  • 118 Boursier J, Vergniol J, Guillet A. , et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 2016; 65 (03) 570-578
    CrossrefPubMedGoogle Scholar
  • 119 Besutti G, Valenti L, Ligabue G. , et al. Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: a systematic review. Liver Int 2019; 39 (08) 1521-1534
    CrossrefPubMedGoogle Scholar
  • 120 Fraquelli M, Rigamonti C, Casazza G. , et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56 (07) 968-973
    CrossrefPubMedGoogle Scholar
  • 121 Tsai E, Lee T-P. Diagnosis and evaluation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography. Clin Liver Dis 2018; 22 (01) 73-92
    CrossrefPubMedGoogle Scholar
  • 122 Karlas T, Kollmeier J, Böhm S. , et al. Noninvasive characterization of graft steatosis after liver transplantation. Scand J Gastroenterol 2015; 50 (02) 224-232
    CrossrefPubMedGoogle Scholar
  • 123 Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: a meta-analysis. PLoS One 2017; 12 (09) e0185192
    CrossrefPubMedGoogle Scholar
  • 124 Winters AC, Mittal R, Schiano TD. A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient. Clin Transplant 2019; 33 (10) e13700
    PubMedGoogle Scholar
  • 125 Neuschwander-Tetri BA, Loomba R, Sanyal AJ. , et al; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385 (9972): 956-965
    CrossrefPubMedGoogle Scholar
  • 126 Younossi Z, Ratziu V, Loomba R. , et al. GS-06-positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH. J Hepatol 2019; 70 (01) e5
    PubMedGoogle Scholar